Список литературы

Поставить закладку

Glynne-Jones R., Nilsson P. J., Aschele C., Goh V., Peiffert D., Cervantes A., Arnold D., European Society for Medical O., European Society of Surgical O., European Society of R., Oncology. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up // Eur J Surg Oncol. ‒ 2014. ‒ T. 40, № 10. ‒ C. 1165-76.
Hoots B. E., Palefsky J. M., Pimenta J. M., Smith J. S. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions // Int J Cancer. ‒ 2009. ‒ T. 124, № 10. ‒ C. 2375-83.
Nelson V. M., Benson A. B., 3rd. Epidemiology of Anal Canal Cancer // Surg Oncol Clin N Am. ‒ 2017. ‒ T. 26, № 1. ‒ C. 9-15.
DeVita, Hellman, and Rosenberg"s cancer: principles & practice of oncology. / DeVita V. T., Lawrence T. S., Rosenberg S. A.: Lippincott Williams & Wilkins, 2008.
Correa J. C., Cummings B., Easson A. M. Anal Cancer // Surgical Oncology ManualSpringer, 2016. – C. 21-39.
Minsky B. D., Guillem J. G. Neoplasms of the anus // Holland‐Frei Cancer Medicine. ‒ 2016. ‒ C. 1-12.
Henkenberens C., Toklu H., Tamme C., Bruns F. Clinical value of squamous cell carcinoma antigen (SCCAg) in anal cancer–a single-center retrospective analysis // Anticancer research. ‒ 2016. ‒ T. 36, № 6. ‒ C. 3173-3177.
Williams M., Swampillai A., Osborne M., Mawdsley S., Hughes R., Harrison M., Harvey R., Glynne-Jones R., Mount Vernon Colorectal Cancer N. Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin // Cancer. ‒ 2013. ‒ T. 119, № 13. ‒ C. 2391-8.
Reginelli A., Granata V., Fusco R., Granata F., Rega D., Roberto L., Pellino G., Rotondo A., Selvaggi F., Izzo F., Petrillo A., Grassi R. Diagnostic performance of magnetic resonance imaging and 3D endoanal ultrasound in detection, staging and assessment post treatment, in anal cancer // Oncotarget. ‒ 2017. ‒ T. 8, № 14. ‒ C. 22980-22990.
Granata V., Fusco R., Reginelli A., Roberto L., Granata F., Rega D., Rotondo A., Grassi R., Izzo F., Petrillo A. Radiological assessment of anal cancer: an overview and update // Infectious agents and cancer. ‒ 2016. ‒ T. 11, № 1. ‒ C. 52.
Mistrangelo M., Franco P., Testa V., Lesca A., Bellò M., Morino M. Sentinel Node Biopsy for Anal Carcinoma // Clin Oncol. ‒ 2017. ‒ T. 2. ‒ C. 1311.
Van den Wyngaert T., Strobel K., Kampen W. U., Kuwert T., van der Bruggen W., Mohan H. K., Gnanasegaran G., Delgado-Bolton R., Weber W. A., Beheshti M., Langsteger W., Giammarile F., Mottaghy F. M., Paycha F., Bone E., Joint C., the Oncology C. The EANM practice guidelines for bone scintigraphy // Eur J Nucl Med Mol Imaging. ‒ 2016. ‒ T. 43, № 9. ‒ C. 1723-38.
Starck S. A., Rosendahl L. Comments on Van den Wyngaert et al., The EANM practice guidelines for bone scintigraphy // Eur J Nucl Med Mol Imaging. ‒ 2016. ‒ T. 43, № 12. ‒ C. 2263-2264.
Glynne-Jones R., Meadows H., Wan S., Gollins S., Leslie M., Levine E., McDonald A. C., Myint S., Samuel L., Sebag-Monteﬁore D. EXTRA—a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer // International Journal of Radiation Oncology* Biology* Physics. ‒ 2008. ‒ T. 72, № 1. ‒ C. 119-126.
Meulendijks D., Dewit L., Tomasoa N., Van Tinteren H., Beijnen J., Schellens J., Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option // British journal of cancer. ‒ 2014. ‒ T. 111, № 9. ‒ C. 1726.
Gunderson L. L., Winter K. A., Ajani J. A., Pedersen J. E., Moughan J., Benson A. B., 3rd, Thomas C. R., Jr., Mayer R. J., Haddock M. G., Rich T. A., Willett C. G. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving ﬂuorouracil/mitomycin versus ﬂuorouracil/cisplatin // J Clin Oncol. ‒ 2012. ‒ T. 30, № 35. ‒ C. 4344-51.
James R. D., Glynne-Jones R., Meadows H. M., Cunningham D., Myint A. S., Saunders M. P., Maughan T., McDonald A., Essapen S., Leslie M., Falk S., Wilson C., Gollins S., Begum R., Ledermann J., Kadalayil L., Sebag-Monteﬁore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial // Lancet Oncol. ‒ 2013. ‒ T. 14, № 6. ‒ C. 516-24.
Myerson R. J., Garofalo M. C., El Naqa I., Abrams R. A., Apte A., Bosch W. R., Das P., Gunderson L. L., Hong T. S., Kim J. J. Elective clinical target volumes for conformal therapy in anorectal cancer: an RTOG consensus panel contouring atlas // International journal of radiation oncology, biology, physics. ‒ 2009. ‒ T. 74, № 3. ‒ C. 824.
Mitra D., Hong T. S., Horick N., Rose B., Drapek L. N., Blaszkowsky L. S., Allen J. N., Kwak E. L., Murphy J. E., Clark J. W., Ryan D. P., Cusack J. C., Bordeianou L. G., Berger D. L., Wo J. Y. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529 // Adv Radiat Oncol. ‒ 2017. ‒ T. 2, № 2. ‒ C. 110-117.
Wright J. L., Patil S. M., Temple L. K., Minsky B. D., Saltz L. B., Goodman K. A. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity- modulated radiation treatment planning // Int J Radiat Oncol Biol Phys. ‒ 2010. ‒ T. 78, № 4. ‒ C. 1064-72.
Bazan J. G., Hara W., Hsu A., Kunz P. A., Ford J., Fisher G. A., Welton M. L., Shelton A., Kapp D. S., Koong A. C., Goodman K. A., Chang D. T. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal // Cancer. ‒ 2011. ‒ T. 117, № 15. ‒ C. 3342-51.
Dewas C. V., Maingon P., Dalban C., Petitﬁls A., Peignaux K., Truc G., Martin E., Khoury C., Dewas S., Créhange G. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical beneﬁt than 3D conformal chemoradiation in patients with anal cancer? // Radiation Oncology. ‒ 2012. ‒ T. 7, № 1. ‒ C. 201.
Lee A., Albert A., Sheth N., Adedoyin P., Rowley J., Schreiber D. Patterns of care and outcomes of intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for anal cancer // J Gastrointest Oncol. ‒ 2019. ‒ T. 10, № 4. ‒ C. 623-631.
Ghareeb A., Paramasevon K., Mokool P., van der Voet H., Jha M. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy // Ann R Coll Surg Engl. ‒ 2019. – T. 101, № 3. ‒ C. 168-175.
Ortholan C., Resbeut M., Hannoun-Levi J. M., Teissier E., Gerard J. P., Ronchin P., Zaccariotto A., Minsat M., Benezery K., Francois E., Salem N., Ellis S., Azria D., Champetier C., Gross E., Cowen D. Anal canal cancer: management of inguinal nodes and beneﬁt of prophylactic inguinal irradiation (CORS-03 Study) // Int J Radiat Oncol Biol Phys. ‒ 2012. ‒ T. 82, № 5. ‒ C. 1988-95.
Matthews J. H., Burmeister B. H., Borg M., Capp A. L., Joseph D., Thompson K. M., Thompson P. I., Harvey J. A., Spry N. A. T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02 // Radiother Oncol. ‒ 2011. ‒ T. 98, № 1. ‒ C. 93-8.
Zilli T., Betz M., Bieri S., Ris F., Roche B., Roth A. D., Allal A. S. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control // Int J Radiat Oncol Biol Phys. ‒ 2013. ‒ T. 87, № 1. ‒ C. 60-6.
Janssen S., Zu Eissen J. M., Kolbert G., Bremer M., Karstens J. H., Meyer A. Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome // International journal of colorectal disease. ‒ 2009. ‒ T. 24, № 12. ‒ C. 1421.
Meyer A., Meier Zu Eissen J., Karstens J. H., Bremer M. Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome // Acta Oncol. ‒ 2006. ‒ T. 45, № 6. ‒ C. 728-35.
Konski A., Garcia M., Jr., John M., Krieg R., Pinover W., Myerson R., Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08 // Int J Radiat Oncol Biol Phys. ‒ 2008. ‒ T. 72, № 1. ‒ C. 114-8.
Rao S., Sclafani F., Guren M. G., Adams R. A., Monteﬁori D., Segelov E., Bryant A., Peckitt C., Roy A., Seymour M. T. InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-ﬂuorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease- an international rare cancers initiative (IRCI) trial // Annals of Oncology. ‒ 2018. ‒ T. 29.
Faivre C., Rougier P., Ducreux M., Mitry E., Lusinchi A., Lasser P., Elias D., Eschwege F. 5- ﬂuorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer // Bulletin du cancer. ‒ 1999. ‒ T. 86, № 10. ‒ C. 861-5.
Mondaca S. n., Chatila W. K., Hechtman J. F., Bates D., Cercek A., Segal N. H., Stadler Z. K., Varghese A. M., Berger M. F., Capanu M. FOLFCIS regimen for treatment of cancer of the anal canal // Book FOLFCIS regimen for treatment of cancer of the anal canal / EditorAmerican Society of Clinical Oncology, 2018.
Kim S., Jary M., André T., Vendrely V., Buecher B., François E., Bidard F.-C., Dumont S., Samalin E., Peiffert D. Docetaxel, Cisplatin, and 5-ﬂuorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study) // BMC cancer. ‒ 2017. – T. 17, № 1. ‒ C. 574.
Morris V. K., Salem M. E., Nimeiri H., Iqbal S., Singh P., Ciombor K., Polite B., Deming D., Chan E., Wade J. L., Xiao L., Bekaii-Saab T., Vence L., Blando J., Mahvash A., Foo W. C., Ohaji C., Pasia M., Bland G., Ohinata A., Rogers J., Mehdizadeh A., Banks K., Lanman R., Wolff R. A., Streicher H., Allison J., Sharma P., Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study // Lancet Oncol. ‒ 2017. ‒ T. 18, № 4. ‒ C. 446- 453.
Ott P. A., Piha-Paul S. A., Munster P., Pishvaian M. J., van Brummelen E. M. J., Cohen R. B., Gomez-Roca C., Ejadi S., Stein M., Chan E., Simonelli M., Morosky A., Saraf S., Emancipator K., Koshiji M., Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal // Ann Oncol. ‒ 2017. ‒ T. 28, № 5. ‒ C. 1036- 1041.
Grifaichi F., Padovani A., Romeo F., Trinca C., Moscetti L., Cortesi E. Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report // Tumori. ‒ 2001. ‒ T. 87, № 1. ‒ C. 58-9.
Lukan N., Strobel P., Willer A., Kripp M., Dinter D., Mai S., Hochhaus A., Hofheinz R. D. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status // Oncology. ‒ 2009. ‒ T. 77, № 5. ‒ C. 293-9.
Barmettler H., Komminoth P., Schmid M., Duerr D. Efﬁcacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer // Case Rep Oncol. ‒ 2012. ‒ T. 5, № 2. ‒ C. 428-33.
Rogers J. E., Ohinata A., Silva N. N., Mehdizadeh A., Eng C. Epidermal growth factor receptor inhibition in metastatic anal cancer // Anti-cancer drugs. ‒ 2016. ‒ T. 27, № 8. ‒ C. 804-808.
Kim D. W., Byer J., Kothari N., Mahipal A., Chang Y. D., Kim R. D. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience // Oncology. ‒ 2017. ‒ T. 92, № 4. ‒ C. 190-196.
Mullen J. T., Rodriguez-Bigas M. A., Chang G. J., Barcenas C. H., Crane C. H., Skibber J. M., Feig B. W. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal // Ann Surg Oncol. ‒ 2007. ‒ T. 14, № 2. ‒ C. 478-83.
Glynne-Jones R., Sebag-Monteﬁore D., Meadows H. M., Cunningham D., Begum R., Adab F., Benstead K., Harte R. J., Stewart J., Beare S., Hackshaw A., Kadalayil L., group A. I. s. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial // Lancet Oncol. ‒ 2017. ‒ T. 18, № 3. ‒ C. 347-356.
Cummings B. J., Keane T. J., O"Sullivan B., Wong C. S., Catton C. N. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-ﬂuorouracil with and without mitomycin C // Int J Radiat Oncol Biol Phys. ‒ 1991. ‒ T. 21, № 5. ‒ C. 1115-25.
Schlienger M., Krzisch C., Pene F., Marin J. L., Gindrey-Vie B., Mauban S., Barthelemy N., Habrand J. L., Socie G., Parc R., et al. Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases // Int J Radiat Oncol Biol Phys. ‒ 1989. ‒ T. 17, № 6. ‒ C. 1141-51.
Brown S. R., Skinner P., Tidy J., Smith J. H., Sharp F., Hosie K. B. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen"s disease) // Br J Surg. ‒ 1999. ‒ T. 86, № 8. ‒ C. 1063-6.
Marchesa P., Fazio V. W., Oliart S., Goldblum J. R., Lavery I. C. Perianal Bowen"s disease: a clinicopathologic study of 47 patients // Dis Colon Rectum. ‒ 1997. ‒ T. 40, № 11. ‒ C. 1286-93.
Polcz M., Chakravarthy A. B., Bailey C. E. Diagnosis and Management of Perianal Skin Tumors // Anal CancerSpringer, 2019. ‒ C. 123-131.
Isik O., Aytac E., Brainard J., Valente M. A., Abbas M. A., Gorgun E. Perianal Paget"s disease: three decades experience of a single institution // Int J Colorectal Dis. ‒ 2016. ‒ T. 31, № 1. ‒ C. 29- 34.
Kachnic L. A., Winter K., Myerson R. J., Goodyear M. D., Willins J., Esthappan J., Haddock M. G., Rotman M., Parikh P. J., Safran H., Willett C. G. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-ﬂuorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal // Int J Radiat Oncol Biol Phys. ‒ 2013. – T. 86, № 1. ‒ C. 27-33.
Ajani J. A., Winter K. A., Gunderson L. L., Pedersen J., Benson A. B., 3rd, Thomas C. R., Jr., Mayer R. J., Haddock M. G., Rich T. A., Willett C. Fluorouracil, mitomycin, and radiotherapy vs ﬂuorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial // JAMA. ‒ 2008. ‒ T. 299, № 16. ‒ C. 1914-21.
Yeung R., McConnell Y., Roxin G., Banerjee R., Urgoiti G. B., MacLean A. R., Buie W. D., Mulder K. E., Vickers M. M., Joseph K. J., Doll C. M. One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity // Curr Oncol. ‒ 2014. ‒ T. 21, № 3. ‒ C. e449-56.
Silver J. K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes // American journal of physical medicine & rehabilitation. ‒ 2013. ‒ T. 92, № 8. ‒ C. 715- 727.
Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery // Int J Surg. ‒ 2017. ‒ T. 39. ‒ C. 156-162.
Gillis C., Li C., Lee L., Awasthi R., Augustin B., Gamsa A., Liberman A. S., Stein B., Charlebois P., Feldman L. S., Carli F. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer // Anesthesiology. ‒ 2014. ‒ T. 121, № 5. ‒ C. 937-47.
Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological prehabilitation before cancer surgery: a systematic review // Annals of surgical oncology. ‒ 2015. ‒ T. 22, № 13. ‒ C. 4117-4123.
Li P., Fang F., Cai J. X., Tang D., Li Q. G., Wang D. R. Fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for colorectal malignancy: a meta-analysis // World J Gastroenterol. ‒ 2013. ‒ T. 19, № 47. ‒ C. 9119-26.
Wren S. M., Martin M., Yoon J. K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward // J Am Coll Surg. ‒ 2010. ‒ T. 210, № 4. ‒ C. 491-5.
de Almeida E. P. M., de Almeida J. P., Landoni G., Galas F., Fukushima J. T., Fominskiy E., de Brito C. M. M., Cavichio L. B. L., de Almeida L. A. A., Ribeiro U., Jr., Osawa E. A., Diz M. P., Cecatto R. B., Battistella L. R., Hajjar L. A. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial // Br J Anaesth. ‒ 2017. ‒ T. 119, № 5. ‒ C. 900-907.
Visser W. S., Te Riele W. W., Boerma D., van Ramshorst B., van Westreenen H. L. Pelvic ﬂoor rehabilitation to improve functional outcome after a low anterior resection: a systematic review // Ann Coloproctol. ‒ 2014. ‒ T. 30, № 3. ‒ C. 109-14.
Finnane A., Janda M., Hayes S. C. Review of the evidence of lymphedema treatment effect // Am J Phys Med Rehabil. ‒ 2015. ‒ T. 94, № 6. ‒ C. 483-98.
Cheville A. L., Kollasch J., Vandenberg J., Shen T., Grothey A., Gamble G., Basford J. R. A home- based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial // J Pain Symptom Manage. ‒ 2013. ‒ T. 45, № 5. ‒ C. 811-21.
Jeon J., Sato K., Niedzwiecki D., Ye X., Saltz L. B., Mayer R. J., Mowat R. B., Whittom R., Hantel A., Benson A., Wigler D. S., Atienza D., Messino M., Kindler H., Venook A., Fuchs C. S., Meyerhardt J. A. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance // Clin Colorectal Cancer. ‒ 2013. ‒ T. 12, № 4. ‒ C. 233-8.
Mustian K. M., Alfano C. M., Heckler C., Kleckner A. S., Kleckner I. R., Leach C. R., Mohr D., Palesh O. G., Peppone L. J., Piper B. F., Scarpato J., Smith T., Sprod L. K., Miller S. M. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta- analysis // JAMA Oncol. ‒ 2017. ‒ T. 3, № 7. ‒ C. 961-968.
Kinkead B., Schettler P. J., Larson E. R., Carroll D., Sharenko M., Nettles J., Edwards S. A., Miller A. H., Torres M. A., Dunlop B. W., Rakofsky J. J., Rapaport M. H. Massage therapy decreases cancer- related fatigue: Results from a randomized early phase trial // Cancer. ‒ 2018. ‒ T. 124, № 3. ‒ C. 546-554.
Bensadoun R. J., Nair R. G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy // Photomed Laser Surg. ‒ 2015. ‒ T. 33, № 10. ‒ C. 487-91.